Article

CD22 CAR T-cell Therapy Effective After CD19 CAR Therapy Failure in Children With B-ALL

A CAR T-cell therapy specific for CD22 was safe and provided high response rates for pediatric patients with B-cell acute lymphoblastic leukemia who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment.

blood cells

A novel chimeric antigen receptor (CAR) T-cell therapy specific for CD22 was safe and provided high response rates for pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment, according to early findings reported at the 2018 EHA Congress.

In 15 efficacy-evaluable patients with relapsed or refractory B-ALL, the objective response rate was 86.7% at 30 days’ post-infusion. Eighty percent of patients achieved complete remission (CR) or CR with incomplete count recovery (CRi). Partial remission was achieved in 6.7% of patients. The 6-month progression-free survival (PFS) rate was 91.7% in responding patients. Additionally, the procedure was well-tolerated with cytokine release syndrome (CRS) of mild to medium severity (grade 0 to 2) reported in all patients following the immunotherapy.

Lead investigator Jing Pan, MD, Beijing Boren Hospital, Beijing, China, underscored the need for new therapies in relapsed or refractory B-ALL, due to the high rate of relapse within 1 year following treatment, including with anti-CD19 CAR T-cell therapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT).

“All heavily treated children with relapsed or refractory B-ALL will die with current therapies,” she stated. However, she noted, that with the CD22 CAR T-cell therapy, “No patient, not even those who had received prior allo-HSCT, had severe side effects or died during CD22 CAR-T therapy.”

The need for new therapies after the development of resistance to CD19-directed CAR T-cell therapy prompted Pan and colleagues to evaluate the efficacy and safety of a CAR T-cell directed to CD22, a marker found on mature B cells that has been identified as a resistance mechanism to current CD19-targeted therapies.

Their study enrolled 15 pediatric patients with relapsed or refractory B-ALL between July 6, 2017, and January 8, 2018, at the Beijing Boren Hospital. The median age of patients was 8 years (range, 2-18) and the median time since diagnosis was 21 months (range, 5-84). All patients were refractory to chemotherapy and 14 had relapsed or had no response to CD19 CAR T-cell therapy. Four patients had relapsed following allo-HSCT but had not received prior CAR T-cell therapy.

At baseline, all patients tested positive for CD22 expression on leukemia cells. One patient was found to have weak CD19 expression, possibly leading to a lack of response to prior anti-CD19 therapy. Eleven patients entered the trial with hematologic relapse with 42% bone marrow blast cells (range, 5%-95.5%). Two patients were minimal residual disease-positive by flow-cytometry (FCM-MRD) and 2 patients had developed extramedullary diseases (EMDs) at study entry.

The patients were monitored for CAR T cell expansion after infusion, which revealed that peak expansion of CD3+ cells ranged from 3.2% to 71.7% by day 11 (±1.8 days). At the 30-day assessment, all but 2 patients had shown response to the CAR T-cell therapy. The two patients who did not respond, continued to have strong CD22 expression.

Of those with hematologic relapse at baseline, 10 of 11 achieved a CR or CRi, with 9 achieving FCM-MRD negativity (82%). One of the 2 MRD-positive patients converted to an MRD-negative response with the CD22 CAR T cell infusion. Additionally, 1 of the 2 patients with EMDs achieved a CR and the other achieved a PR.

With a median follow-up of 108 day, 6 patients had gone on to receive subsequent allo-HSCT. Of those achieving a CR/CRi, 11 continued to be progression-free at the analysis. The one relapsing patient had relapsed at 50 days.

“CD22-directed CAR-T cell therapy brings hope to patients with relapse or refractory B-ALL who have failed CD19 CAR-T cell therapy,” Pan said.

Severe CRS (grade 3/4) was not reported in the study, with most events being grade 1 and just 3 patients having grade 2 events. Grade 1 neurotoxicity was experienced by 2 patients. Overall, there was no significant difference in CRS found between patients who received and did not receive prior allo-HSCT (P = .41).

Further analysis from the study is ongoing. FCM-MRD scans had been conducted at months 1 and 3, Pan noted, with longer observation needed to determine the long-term outcomes.

Pan J, Deng B, Liu S, et al. Efficacy and safety of CD22-directed CAR-T cell therapy in 15 pediatric refractory or relapsed B acute lymphoblastic leukemia patients. Presented at: 2018 EHA Congress; June 14-17, 2018; Stockholm, Sweden. Abstract S832.

<<< 2018 European Hematology Association Congress

The cells used in the trial were manufactured using a lentiviral vector to transduce a CAR derived from a humanized CD22 antibody. The CAR T-cell therapy was also engineered to have a 4-1BB costimulatory domain and a CD3-zeta signaling domain. The manufacturing process, which use peripheral blood mononuclear cells, took 7 to 8 days following leukapheresis, according to the investigators. The agent was administered at a median dose of 8.2 × 105/kg in non-transplanted patients and at a median of 0.9 × 105/kg for previously transplanted patients.

Related Videos
David Schiff, MD
Timothy Gershon, MD, PhD
Jordan Hansford, MD
J. Bradley Elder, MD
Rimas V. Lukas, MD
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Minoo Battiwalla, MD, MS
Paolo Caimi, MD
Jennifer Scalici, MD